1. ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class — Gilead, Galapagos share 52-week update on filgotinib — UPS gets clearance to expand medical drone delivery service across US — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Alder

Discussion in 'Biotech Startups' started by anonymous, Jun 6, 2019 at 2:09 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

     
  2. anonymous

    anonymous Guest

    Big bucks?! HAHAHAHAHAHHAHAHAHAHHAHAHAHA
     
  3. anonymous

    anonymous Guest

    What's everybody's take on this company? I still see numerous openings. Wheres the base, car allowance, etc??? Anyone hired on the rep side have any input?
     
  4. anonymous

    anonymous Guest

    isnt syneos involved in their recruiting? Right off the bat , that should make you question this start-up. Syneos is a shithole primary care operation.. bottom of the barrel
     
  5. anonymous

    anonymous Guest


    Princeton one is. Syneos also recruits for start ups, especially small ones that have a small HR department. P.s- you're writing is bottom of the barrel. Derp.....
     
  6. anonymous

    anonymous Guest

    Your**
     
  7. anonymous

    anonymous Guest

    Alder is not a risk worth taking. Launching a “same as existing” product, except it’ll be infused vs self inject. How many people do you know who want to shut down their day to go get an infusion? It’s a very bad bet. To top it off, they’ve stocked their management ranks with people who were life long big pharma people. They have no idea how to build this and that is reflected in their commercial build out. This one will go bad very quickly. Look for layoffs within 6 months of launch. I wish it weren’t the case because more new drugs/choices are always great, but that’s just not the time we are in. Your product needs to innovate in some way and there just isn’t much of that either with Alder or many other small companies right now. If you are out of work, take it. If you have a job, keep looking.
     
  8. anonymous

    anonymous Guest

    P1 could mess up a wet dream.
     
  9. anonymous

    anonymous Guest

    Good luck Getting people now that got bought out
     
  10. anonymous

    anonymous Guest

    jobs are on hold. check back in 2 months.
     
  11. anonymous

    anonymous Guest

    Terrible. They will fire the Alder managers. Don't even attempt to join Lundbeck...they are terrible. Terrible that you wasted time interviewing...but better to know now, then later